Assessment of Efficacy and Safety of Perifosine, Bortezomib and Dexamethasone in Multiple Myeloma Patients
Public ClinicalTrials.gov record NCT01002248. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase III Randomized Study to Assess the Efficacy and Safety of Perifosine Added to the Combination of Bortezomib and Dexamethasone in Multiple Myeloma Patients
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is a randomized Phase III study to evaluate the efficacy and safety of perifosine when added to the combination of bortezomib and dexamethasone in multiple myeloma patients who have relapsed on a prior bortezomib treatment regimen.
Study identification
- NCT ID
- NCT01002248
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 135 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Dec 2009 (Type not available)
- Primary completion
- Mar 2013 (Actual)
- Completion
- Mar 2013 (Actual)
- Last update posted
- Feb 9, 2018
2009 – 2013
United States locations
- U.S. sites
- 39
- U.S. states
- 15
- U.S. cities
- 38
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Not listed | La Verne | California | 91750 | — |
| Not listed | San Francisco | California | 94143 | — |
| Not listed | San Pablo | California | 94806 | — |
| Not listed | Aurora | Colorado | 80012 | — |
| Not listed | Boulder | Colorado | 80303 | — |
| Not listed | Colorado Springs | Colorado | 80909 | — |
| Not listed | Denver | Colorado | 80218 | — |
| Not listed | Lakewood | Colorado | 80228 | — |
| Not listed | Littleton | Colorado | 80120 | — |
| Not listed | Longmont | Colorado | 80501 | — |
| Not listed | Parker | Colorado | 80138 | — |
| Not listed | Pueblo | Colorado | 81008 | — |
| Not listed | Thornton | Colorado | 80260 | — |
| Not listed | Niles | Illinois | 60714 | — |
| Not listed | Winfield | Illinois | 60190 | — |
| Not listed | Baltimore | Maryland | 21201 | — |
| Not listed | Columbia | Maryland | 21044 | — |
| Dana Farber Cancer Institute | Boston | Massachusetts | 02115 | — |
| Not listed | Morristown | New Jersey | 07960 | — |
| Not listed | Great Neck | New York | 11042 | — |
| Not listed | Fargo | North Dakota | 58122 | — |
| Not listed | Portland | Oregon | 97225 | — |
| Not listed | Tualatin | Oregon | 97062 | — |
| Not listed | Kingsport | Tennessee | 37660 | — |
| Not listed | Bedford | Texas | 76022 | — |
| Not listed | Dallas | Texas | 75246 | — |
| Not listed | Fort Worth | Texas | 76104 | — |
| Not listed | Kerrville | Texas | 78028 | — |
| Not listed | San Antonio | Texas | 78217 | — |
| Not listed | San Antonio | Texas | 78229 | — |
| Not listed | Tyler | Texas | 75702 | — |
| Not listed | Ogden | Utah | 84403 | — |
| Not listed | Christiansburg | Virginia | 24073 | — |
| Not listed | Roanoke | Virginia | 24014 | — |
| Not listed | Salem | Virginia | 24153 | — |
| Not listed | Seattle | Washington | 98133 | — |
| Not listed | Spokane | Washington | 99202 | — |
| Not listed | Vancouver | Washington | 98686 | — |
| Not listed | Milwaukee | Wisconsin | 53226 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 47 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01002248, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Feb 9, 2018 · Synced Oct 20, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT01002248 live on ClinicalTrials.gov.